A10, a web app software company, has generated $187.5m from its initial public offering, which saw Mitsui divested $28.3m of shares.

The kidney disease treatment developer, which has secured funding from Novartis and Novo, has raised $106.9m after underwriters took up the option to buy additional shares.

NephroGenex has closed an initial public offering of 3.1 million shares of common stock.

US-based Genocea Biosciences has raised an approximate net value of $61.4m from selling 5.5 millions shares of common stock at a price of $12 per share in an initial public offering.

Alder, which is developing antibodies to fight migraine and arthritis, secured $38m in a 2012 venture round backed by Novo and TPG, and will use the money from the initial public offering to forward testing.

The aldehyde disease specialist, in which Johnson & Johnson owns a 44.5% stake, could potentially raise up to $27.6m from the initial public offering.

Kaiser Permanente-backed Agile plans to use the proceeds from its initial public offering to support clinical trials of its lead product candidate, a weekly contraceptive patch.

Weibo has become the latest Chinese company to tap the US public markets, targeting $500 million from its initial public offering, and plans to leverage its partnership with minority shareholder Alibaba to maxmise advertising revenue.

Cleveland Clinic-backed healthcare services analytics provider Castlight Health has closed a $204.24m initial public offering

Internet company Yahoo to sell a stake of up to 10% in Alibaba, China's largest e-commerce company, in what will likely be the largest IPO in the US since Facebook.